They include: (1) Intra-tumoral IL-12 DNA plasmid (pDNA) [ID: NCT00323206, phase I clinical trials in patients with malignant melanoma]; (2) Intra-tumoral VCL-IM01 (encoding IL-2) [ID: NCT00223899; Phase I clinical trials in patients with metastatic melanoma]; (3) Xenogeneic tyrosinase DNA vaccine [ID: NCT00471133, Phase I clinical trials in patients with melanoma]; (4) VGX-3100TM [ID: NCT00685412, Phase I clinical trials for HPV infections]; and (5) IM injection of prostate-specific membrane antigen (PSMA)/pDOM fusion gene [ID: UK-112, Phase I/II clinical trials for prostate cancer] [113]. The gene discussed is FOLH1; the disease is prostate cancer.